Proactive Investors - Run By Investors For Investors

Pharmaxis gains new substantial holder with 6.89% interest

The company is developing a pipeline of products to treat inflammation and fibrosis.
Pharmaxis gains new substantial holder with 6.89% interest
Pharmaxis' top 20 shareholders held 68.6% of the company end of 2018

Pharmaxis Ltd (ASX:PXS) has gained a substantial holder in D&A Income Limited which now holds more than 27 million Pharmaxis shares representing a 6.89% interest.

D&A initially held abut 8 million shares but purchased a further 19.1 million late last month for a cash consideration of more than $5 million.


Pharmaxis is an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval.

The company’s development pipeline focuses on its expertise in amine oxidase chemistry and includes:

  • A series of lysyl oxidase like 2 (LOXL2) inhibitors targeting fibrotic diseases of the liver, heart, kidney and lunch that recently completed phase-one clinical trials;

  • A lysyl oxidase (LOX) inhibitor in development for pancreatic cancer that recently completed preclinical development; and

  • A potent inhibitor of semicarbazide-sensitive amine oxidase (SSAO) called BI 1467335 to develop treatment for the liver-related condition non-alcoholic steatohepatitis (NASH) and other inflammatory diseases.

Pharmaxis manufactures and exports its approved products from its facility in Sydney, including Bronchitol for the treatment of cystic fibrosis and Aridol, a lung function test for asthma.

View full PXS profile View Profile

Pharmaxis Ltd Timeline

Related Articles

May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
man with erectile dysfunction
June 17 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
genedrive device
July 16 2019
Here we take a closer look at Genedrive PLC (LON:GDR)

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use